Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Testosterone Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy MP 5.01.23

    Testosterone Replacement Therapies

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.23 alerts

    Get alerted when Policy MP 5.01.23 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines clinical background, formulations, regulatory context, and evidence review for testosterone replacement therapy in individuals with androgen deficiency and clinical symptoms of hypogonadism; intended for clinicians and prior authorization reviewers.

    Policy Summary
    PayerBluecross Idaho
    PolicyTestosterone Replacement Therapies
    Policy CodePolicy MP 5.01.23
    Change TypeNo material change
    Effective DateOct 30, 2025
    Last ReviewOct 30, 2025
    Next Review DateOct 30, 2025
    Key ActionPrior authorization must document symptomatic hypogonadism and a confirmed total testosterone level consistent with trials (≤300 ng/dL) and identify the formulation requested.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≤300 ng/dLtestosterone threshold (trial inclusion)
    4 RCTsplacebo-controlled RCTs (Ponce et al)
    5,246TRAVERSE cardiovascular RCT N
    RR ~8.14safety signal (erythrocytosis RR)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    multipleformulations described

    Coverage Criteria

    Initial therapy coverage criteria

    Covered when ALL of the following are met (as reflected in the RCT-based evidence cited):

    Population and diagnosis: Patient has androgen deficiency with clinical symptoms of hypogonadism

    Population of interest described in policy and in RCT inclusion criteria

    Biochemical confirmation: Documented total testosterone measurement at or below the trial-based threshold<=300 ng/dL

    Threshold used in the Endocrine Society–commissioned systematic review (Ponce et al. 2018) and trial inclusion criteria

    Symptom correlation: Presence of ≥1 signs or symptoms of hypogonadism consistent with trial eligibility (e.g., decreased libido, impaired mobility or vitality where applicable)

    Trials required symptomatic hypogonadism in addition to low testosterone

    Absence of exclusionary conditions: No history of prostate cancer, not at high risk for prostate cancer, IPSS ≤19, no condition known to cause hypogonadism, and not at high cardiovascular risk per trial exclusions

    NIH trial exclusion criteria and other RCTs excluded these conditions

    Appropriate formulation selection and rationale: Requested testosterone formulation (e.g., topical, intramuscular, subcutaneous pellet, oral where appropriate) is selected with clinical justification documented

    Formulation choice should consider absorption, dosing frequency, and route-specific risks; prior authorization should identify formulation

    Evidence-based coverage considerations

    Covered when evidence demonstrates likely benefit and trial-like patient selection is met

    Trial-consistent diagnostic criteria: Patient meets symptomatic hypogonadism criteria and has documented low total testosterone consistent with trial thresholds (<=300 ng/dL or, for certain NIH trials, <275 ng/dL)see associated numeric thresholds

    Ponce et al (2018) and NIH trials used these thresholds for inclusion

    No trial exclusion criteria present: Patient does not have conditions excluded from major RCTs (history of prostate cancer, high prostate-cancer risk, IPSS >19, conditions known to cause hypogonadism, or high cardiovascular risk)

    Exclusion criteria from NIH-sponsored RCTs and other trials

    Expected benefit aligns with evidence: Intended therapeutic goal is one of the outcomes for which RCT evidence showed benefit (e.g., improvements in libido/sexual function, lean body mass, bone density, or metabolic parameters in select populations)

    Benefits and harms summarized in systematic reviews and RCTs; document which outcome is targeted

    Subpopulation evidence summaries

    Evidence-supported effects observed in specific subpopulations

    HIV infection with weight loss: RCTs and meta-analyses in HIV-infected men with weight loss demonstrated modest increases in body weight (~0.99–1.1 kg), fat-free mass and lean body mass, and some improvements in muscle strength and depression scores in select trials

    Findings limited by heterogeneity across trials

    Chronic systemic steroid therapy: Pooled RCTs in men receiving chronic steroid treatment showed increased lean body mass (~2.3 kg), decreased fat mass (~3.1 kg), and a ~4% improvement in lumbar spine BMD

    Trials were small and short-term; no femoral neck BMD benefit observed

    Evidence considerations — type 2 diabetes

    Clinical evidence considerations for populations reviewed

    Population definition—type 2 diabetes: Patient population is men with androgen deficiency and type 2 diabetes; the intended therapy goal includes metabolic outcomes such as improved glycemic control and lipid parameters

    PICO used to select literature for this population; see systematic reviews summarizing metabolic improvements

    Evidence of metabolic benefit: Systematic reviews and RCTs report improvements in fasting glucose, fasting insulin, HOMA-IR, and HbA1c and some lipid measures with testosterone in hypogonadal men with type 2 diabetes

    Kumar et al (2022), Zhang et al (2018), and Cai et al (2014) provide pooled estimates but note short follow-up and heterogeneity

    Evidence limitations and safety concerns: Trials in type 2 diabetes often have short follow-up, variable dosing regimens, and possible selective reporting bias; potential increased adverse events in diabetic populations may offset metabolic benefits

    Authors caution benefits may be outweighed by risks in diabetics

    Evidence considerations — older men without definite hypogonadism

    Population and outcomes considered

    Population definition—older men without definite hypogonadism: Population includes older men with low testosterone levels but without pathologic hypogonadism; comparator is typically no testosterone replacementnot specified

    Outcomes of interest include survival, symptoms, morbid events, functional outcomes, and quality of life

    Limited efficacy on global functional outcomes: Randomized trials in this population generally do not demonstrate consistent improvements in functional status, muscle strength, or overall quality of life despite increases in lean body mass and decreases in fat mass in some studies

    Large and small RCTs (e.g., Legros et al, Emmelot-Vonk, Mok et al) report mixed results; benefits often do not translate to functional gains

    Safety uncertainty affecting coverage: Adverse event profile in older men is not well-defined; concerns about prostate-related and cardiovascular harms create uncertainty in the risk–benefit assessment

    Evidence summaries relevant to coverage

    Evidence-based findings relevant to coverage decisions:

    Efficacy—men without definite hypogonadism: Most RCTs in older men without pathologic hypogonadism show no consistent clinically meaningful improvements in functional status, muscle strength, or quality of life; some trials report increased lean body mass and reduced body fat

    Evidence summarized from several RCTs and systematic reviews

    Cardiovascular safety: Systematic reviews and a large noninferiority RCT (TRAVERSE, N=5,246) show no overall increase in major adverse cardiovascular events; some meta-analyses reported early increased event rates in older subgroups during the first 12 months

    TRAVERSE trial demonstrated noninferiority for cardiovascular outcomes; other reviews report mixed findings particularly in early follow-up and older patients

    Prostate-related outcomes: Short-term transdermal testosterone trials show small increases in PSA, but meta-analyses and RCTs have not demonstrated a consistent association with prostate cancer or long-term adverse prostate outcomes

    PSA changes noted in systematic reviews; long-term prostate risk remains uncertain

    Buccal testosterone is no longer available in the United States; therefore use of buccal preparations is not applicable for coverage or prior-authorization consideration.

    Placebo-controlled randomized trials (notably the NIH-sponsored trials) excluded men with a history of prostate cancer or those at high risk for prostate cancer, men with an International Prostate Symptom Score (IPSS) > 19, conditions known to cause hypogonadism, and men at high cardiovascular risk; these trial exclusion criteria should be considered when assessing whether an individual matches the evidence base for benefit and safety reporting.

    The evidence selection process excluded studies with duplicative or overlapping populations to avoid double-counting and to preserve the independence of trial results in the systematic review and synthesis.

    These sections do not present a single explicit exclusion list for all reviewed studies; however, authors reviewing testosterone use in men with type 2 diabetes note that trials often had short follow-up, variable dosing, and selective reporting bias, and that the increased risk of adverse events in the diabetic population may limit the net benefit and influence coverage decisions.

    The document emphasizes uncertainty in the adverse-event profile of testosterone therapy — particularly prostate-related and cardiovascular outcomes — and notes that this uncertainty constrains clear conclusions about net clinical benefit for many populations, limiting the strength of recommendations for broader use.

    The Endocrine Society recommends against testosterone therapy in men who are planning fertility in the near term and in men with breast or prostate cancer, a palpable prostate nodule or induration, a prostate-specific antigen (PSA) level > 4 ng/mL (or PSA > 3 ng/mL with high prostate-cancer risk without further urologic evaluation), elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, recent myocardial infarction or stroke (within 6 months), or thrombophilia.

    Use of testosterone for populations or indications not represented in the placebo-controlled randomized trial evidence—specifically men without documented symptomatic hypogonadism and without biochemical confirmation consistent with trial eligibility—lacks the trial-based support cited in the evidence synthesis and therefore is not supported by the RCT evidence base referenced in this policy.

    For non-sexual complaints (for example, attempts to improve energy, depression, overall quality of life, or cognition), randomized trials and meta-analyses have not consistently demonstrated clinically meaningful benefit; evidence for these indications is limited and inconsistent and does not reliably support routine testosterone replacement for non-sexual symptoms.

    Although no explicit blanket "medically necessary" or "not medically necessary" statements appear in the cited chunks, the body of evidence is limited by small trial sizes, short follow-up, and heterogeneity; these limitations may lead to restrictions on coverage for indications or populations lacking demonstrated benefit.

    No explicit not-medically-necessary determination is stated in the cited sections regarding men with type 2 diabetes, but reviewers note uncertainty and the potential that treatment risks may outweigh benefits in some diabetic patients, which could justify coverage restrictions in that population.

    In older men with low testosterone but without definite pathologic hypogonadism, randomized trials generally did not show clinically meaningful improvements in functional status, muscle strength, or quality of life despite modest increases in lean body mass; this lack of demonstrable functional benefit limits support for routine replacement in this population absent clear hypogonadism and symptomatic improvement.

    Guideline recommendations advise against testosterone therapy in men planning fertility in the near term and in men with certain active conditions (see exclusions above); these guidance-based recommendations should inform coverage decisions and prior-authorization review when those clinical circumstances are present.

    Coding

    Codes listed in policymixed
    11980Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets beneath the skin).
    96372Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular (Injection, testosterone cypionate, 1 mg).
    J1071Injection, testosterone cypionate, 1 mg.
    J1073Testosterone pellet, 75 mg.
    J3121Injection, testosterone enanthate, 1 mg.
    J3145Injection, testosterone undecanoate, 1 mg.
    E29.1Testicular hypofunction (ICD-10-CM).
    3E013VJPercutaneous administration of hormone (ICD-10-PCS).
    inv-20: Total testosterone — threshold used in cited RCTs: ≤300 ng/dL.
    Threshold (RCT-based)Total testosterone ≤300 ng/dL
    Evidence sourcePonce et al (Endocrine Society–commissioned systematic review of placebo‑controlled RCTs)
    ContextApplied to symptomatic hypogonadism trial inclusion (men with total testosterone <300 ng/dL at screening)
    inv-21: Total testosterone — <=300 ng/dL (Ponce trials) and <275 ng/dL (NIH trials).
    Ponce trials thresholdTotal testosterone ≤300 ng/dL (Ponce et al. systematic review trials)
    NIH trials thresholdTotal testosterone <275 ng/dL (eligibility in NIH‑sponsored trials)

    Provider Actions & Prior Authorization

    Prior Authorization

    Formulation-specific PA and diagnostic confirmation

    Prior authorization must identify the specific testosterone formulation requested (oral, nasal, intramuscular, patch, gel, pellet, or subcutaneous) and provide documentation of symptomatic hypogonadism and a supporting total testosterone measurement consistent with trial selection (testosterone level ≤300 ng/dL). The request should include clinical rationale for the chosen formulation given differing absorption, dosing frequency, and route-specific adverse-effect profiles.

    • List the formulation requested (oral, nasal, IM, patch, gel, pellet, subcutaneous).
    • Include documentation of symptoms/signs of hypogonadism and a measured total testosterone value (≤300 ng/dL as used in cited RCTs).
    • Explain rationale for formulation choice considering absorption, dosing frequency, and route-specific risks.
    Prior Authorization

    Attest symptomatic low testosterone and absence of exclusions

    Prior authorization must attest the patient has symptomatic hypogonadism with a documented low total testosterone consistent with trial inclusion (≤300 ng/dL or the NIH trials’ <275 ng/dL) and confirm that trial-based exclusionary conditions (e.g., prostate cancer history, high prostate-cancer risk, IPSS >19, conditions causing hypogonadism, or high cardiovascular risk) are absent.

    Background & Rationale

    The policy background notes that testosterone replacement therapy is indicated for androgen deficiency with clinical symptoms of hypogonadism, and multiple FDA‑approved formulations exist (intramuscular, oral, topical, subcutaneous, nasal); buccal preparations are no longer marketed in the U.S. The evidence base referenced (placebo-controlled RCTs) enrolled men with symptomatic hypogonadism and biochemical confirmation (total testosterone thresholds used in trials are cited elsewhere in the policy).

    Definitions

    inv-53: Symptomatic hypogonadism — Presence of clinical signs or symptoms of androgen deficiency plus low total testosterone (threshold used in cited RCTs: ≤300 ng/dL).
    DefinitionSymptomatic hypogonadism: presence of clinical signs or symptoms of androgen deficiency plus low total testosterone
    Numeric thresholdTotal testosterone ≤300 ng/dL as used in cited RCTs
    Evidence basisDefined consistent with inclusion criteria in placebo‑controlled RCTs summarized by Ponce et al.
    inv-54: Symptomatic hypogonadism — Presence of signs or symptoms of androgen deficiency plus a low total testosterone measurement (trial inclusion used total testosterone <...).
    Definition (trial wording)Presence of signs or symptoms of androgen deficiency plus a low total testosterone measurement
    Trial inclusion thresholds

    Revision History

    2025-10-30policy_reissueLatest

    Policy replaced and updated with literature through May 19, 2025; references added and updated; policy statements unchanged.

    2024-09-26literature_update

    Policy updated with literature review through May 17, 2023 (adoption noted 09/26/2024); references added and updated; minor editorial refinements to policy statements.

    2022-07-28literature_update
    Policy Summary
    PayerBluecross Idaho
    PolicyTestosterone Replacement Therapies
    Policy CodePolicy MP 5.01.23
    Change TypeNo material change
    Effective DateOct 30, 2025
    Last ReviewOct 30, 2025
    Next Review DateOct 30, 2025
    Key ActionPrior authorization must document symptomatic hypogonadism and a confirmed total testosterone level consistent with trials (≤300 ng/dL) and identify the formulation requested.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & Prior AuthorizationBackground & RationaleDefinitionsRevision History
    Risk assessment and monitoring plan: Provider documents assessment of cardiovascular and prostate risk and a monitoring plan (testosterone levels, hematocrit/hematology, PSA as appropriate)

    Trials were not powered for long-term safety; monitoring aligns with guideline-recommended baseline and follow-up evaluations

    This uncertainty influences coverage decisions for otherwise healthy older men without definite hypogonadism

    Other adverse events: Testosterone therapy is associated with an increased risk of erythrocytosis and has been variably linked to thromboembolic events, lipid changes, sleep apnea worsening, and other safety signals

    Safety findings derive from pooled RCTs, meta-analyses, and observational studies and should inform monitoring and risk assessment

    Usage noteDocumented thresholds used for trial inclusion and for prior‑authorization biochemical confirmation
    inv-22: Age — trial eligibility included >=65 years (NIH trials).
    Age eligibility (NIH trials)>=65 years (general eligibility for NIH trials)
    Trial contextNIH‑sponsored trials enrolled older men with low serum testosterone and specified age‑related functional criteria
    LimitationResults primarily apply to men 65+ with average serum testosterone <275 ng/dL
    inv-23: None specified — placeholder indicating none specified in that chunk.
    None specifiedNo numeric threshold specified in this field
    ContextPlaceholder entry reflecting absence of a specified value in the referenced policy section
    Coding noteRefer to policy code table for listed procedure/diagnosis codes if needed
    • Documented total testosterone value used for decision (≤300 ng/dL or <275 ng/dL where applicable).
    • Statement that exclusionary conditions (history of prostate cancer, high prostate cancer risk, IPSS >19, conditions known to cause hypogonadism, high cardiovascular risk) are not present.
    Prior Authorization

    Document clinical population and rationale

    Prior authorization should document the specific clinical population for which therapy is intended (for example, androgen deficiency on chronic steroid therapy or androgen deficiency with type 2 diabetes) and provide supporting evidence that therapy targets the relevant outcomes (symptoms, body composition, functional measures, or metabolic labs).

    • Identify population (e.g., chronic steroid-associated androgen deficiency; androgen deficiency with type 2 diabetes).
    • Describe targeted outcomes (symptom relief, lean body mass, HbA1c or other metabolic measures) and supporting evidence rationale.
    Prior Authorization

    Indication-specific prior authorization

    Prior authorization must specify the indication (e.g., androgen deficiency with type 2 diabetes or older men with low testosterone without definite hypogonadism) and reference the relevant outcomes and laboratory parameters to be used to evaluate benefit (for example, sexual symptoms, functional outcomes, or HbA1c where applicable).

    • State the indication population (type 2 diabetes; older men with low testosterone without definite hypogonadism).
    • List outcomes or labs that will be used to assess benefit (sexual symptoms, functional measures, metabolic labs such as HbA1c).
    Prior Authorization

    Rationale: limited benefit and mixed safety data

    Prior authorization rationale should note that evidence shows limited clinical benefit for many outcomes in men without clear hypogonadism and that cardiovascular and prostate safety data are mixed or uncertain; authorization should therefore verify documented low testosterone with clinical correlation and consider cardiovascular/prostate risk factors before approval.

    • Acknowledge limited benefits for functional outcomes in men without pathologic hypogonadism.
    • Document consideration of cardiovascular and prostate risk when weighing approval.
    Note

    Product selection per guideline recommendation

    When possible, prescribe commercially manufactured testosterone products rather than compounded preparations and avoid alkylated oral testosterone in accordance with guideline recommendations.

    • Prefer commercially manufactured testosterone products over compounded products.
    • Do not prescribe alkylated oral testosterone.
    Billing Rule

    Codes provided for reference — coverage contingent on plan terms

    The policy lists CPT/HCPCS/ICD-10 and other codes for reference; inclusion of a code does not guarantee coverage or reimbursement and authorization decisions remain subject to the member-specific benefit plan and the written medical policy.

    • Codes are provided for general reference only and may not be all-inclusive.
    • Presence of a code does not imply coverage; benefits depend on plan terms and the medical policy.
    Note

    Formulation selection: consider route-specific factors

    Select formulations with documented clinical rationale considering factors such as dosing frequency, absorption variability, and site- or route-specific adverse effects (e.g., liver toxicity with some oral agents, variable absorption with IM injections, skin irritation with patches, transmission risk with gels, surgical complications with pellets).

    • Consider dosing frequency (daily topical vs. 10–14 week IM depot vs. 3–6 month pellets).
    • Consider absorption variability and route-specific risks (liver toxicity for oral; inconsistent absorption for IM; skin irritation for patches; transmission risk for gels; implantation-site complications for pellets).
    Step Therapy

    Step therapy: testosterone versus no testosterone (no sequencing mandated)

    Step-therapy guidance notes that the primary comparator is no testosterone replacement; these sections do not prescribe a specific stepwise sequencing between formulations—authorization decisions should consider testosterone replacement versus conservative management.

    • Therapy considered is testosterone replacement versus no testosterone.
    • No specific mandatory sequencing between different testosterone formulations is provided in the policy.
    Prior Authorization

    Consider no testosterone replacement as comparator

    Prior authorization should consider no testosterone replacement (watchful waiting or conservative management) as the comparator and document why conservative measures are insufficient before approving therapy.

    • Describe conservative management tried or rationale for not pursuing non-treatment.
    • Document why testosterone replacement is expected to provide benefit over no therapy.
    Note
    Note

    Consider alternatives before initiating testosterone

    Consider conservative (nonpharmacologic) alternatives before initiating testosterone in men without pathologic hypogonadism, given small and inconsistent benefits (mainly increased lean mass and decreased fat without consistent functional improvement).

    • Document consideration or trial of nonpharmacologic alternatives when appropriate.
    • Note that many trials showed increases in lean body mass and decreases in fat but not consistent functional gains.
    Note

    Dose titration: target middle tertile of normal range

    Clinicians should titrate testosterone dosing to achieve a total testosterone concentration in the middle tertile of the normal reference range, documenting dose adjustments and follow-up levels accordingly.

    • Adjust dosing and document measured total testosterone targeted to the middle tertile of the normal range.
    • Record dose changes and subsequent testosterone levels in the medical record.
    Note
    Documentation Required

    Required clinical documentation: symptoms and confirmatory testosterone level

    Documentation submitted with authorization must support symptomatic hypogonadism and include confirmatory laboratory testing consistent with trial criteria (total testosterone ≤300 ng/dL) and description of symptoms/signs used to establish hypogonadism.

    • Provide a morning total testosterone result and note the assay if available.
    • Describe clinical signs or symptoms that meet the definition of symptomatic hypogonadism.
    Documentation Required

    Required documentation elements: baseline testosterone, symptoms, exclusions

    Documentation should include baseline total testosterone level (trial eligibility thresholds used ≤300 ng/dL or <275 ng/dL), presence of symptoms/signs of hypogonadism, and note any exclusionary conditions (e.g., prostate cancer history, elevated IPSS).

    • Include numeric baseline testosterone value and date/time (preferably morning sample).
    • List presence of exclusionary conditions or confirm their absence.
    Documentation Required

    Document diagnosis and clinical context for population of interest

    Document the diagnostic context showing androgen deficiency in the population of interest (for example, androgen deficiency related to chronic steroid therapy or associated with type 2 diabetes) and include the rationale linking therapy to intended outcomes.

    • Specify the clinical population (chronic steroid use, type 2 diabetes, older men without definite hypogonadism).
    • Explain how testosterone therapy is expected to address the patient’s specific clinical problems.
    Documentation Required

    Document which clinical population applies

    For prior authorization, document whether the patient fits the evidence-based populations (e.g., androgen deficiency with type 2 diabetes or older men with low testosterone without definite hypogonadism) and indicate which population applies to the request.

    • State which evidence-based population the patient represents.
    • Include any population-specific details (e.g., comorbid diabetes) that influenced the decision to treat.
    Documentation Required

    Document relevant clinical measures (PSA, hematocrit, body composition, function)

    Document relevant baseline and follow-up clinical measures commonly reported in trials — for example, lean body mass, body fat, functional capacity, muscle strength, sexual symptoms, PSA, hematocrit, and metabolic parameters — as these inform efficacy and safety evaluation.

    • Record baseline PSA and hematocrit and plan for periodic monitoring.
    • Document measures of symptoms and functional outcomes used to assess benefit.
    Documentation Required

    Baseline and monitoring evaluations per guideline guidance

    Obtain a morning total testosterone using an accurate assay for baseline assessment; consider measuring sex hormone–binding globulin and pituitary hormones (LH, FSH) when indicated, and assess prostate-cancer risk before initiation with PSA and consider PSA and prostate monitoring 3–12 months after starting therapy in men aged 55–69 with life expectancy >10 years.

    • Baseline: morning total testosterone; consider SHBG and LH/FSH if needed.
    • Baseline PSA and hematocrit; plan PSA and hematocrit monitoring 3–12 months after initiation where guideline-recommended.
    Billing Rule

    Coding guidance: codes are reference only

    Codes listed in the policy are for general reference only; inclusion of a code does not guarantee coverage or reimbursement and plan-specific benefit determinations apply.

    • Verify coverage and reimbursement based on the member’s specific benefit plan and the written medical policy, not solely on listed codes.
    Denial Risk

    Denial risk: prescribing outside trial-based populations

    Therapy prescribed outside the populations and diagnostic criteria used in the RCT-based systematic review (men with symptomatic hypogonadism and total testosterone ≤300 ng/dL) may be considered unsupported by the cited evidence and at higher risk for denial.

    • If the patient does not meet symptomatic hypogonadism with testosterone ≤300 ng/dL, include justification and supporting evidence for off-trial–population use.
    Denial Risk

    Exclusion criteria that may trigger denial

    Exclusionary conditions used in NIH trials (history of prostate cancer, high prostate-cancer risk, IPSS >19, conditions known to cause hypogonadism, or high cardiovascular risk) were excluded from trial populations and their presence may trigger denial or require further evaluation.

    • If any exclusionary condition is present, provide urologic or cardiology evaluation as appropriate before authorization.
    Denial Risk

    Outcome-based denial risk: lack of demonstrated clinical benefit

    Lack of demonstrated improvement in key outcomes (overall survival, symptoms, morbid events, functional outcomes, quality of life) is a potential basis for denial if evidence does not support benefit for the requested indication.

    • Document objective outcome measures and expected clinical benefit to support approval.
    Denial Risk

    Safety and evidence limitations in type 2 diabetes

    In individuals with type 2 diabetes, benefits on glycemic and lipid measures have been reported but may be offset by increased risk of adverse events; selective reporting bias and short follow-up in trials are additional limitations that may influence coverage decisions.

    • When treating men with diabetes, document careful consideration of risks versus metabolic benefits and cite supporting trial evidence.
    Denial Risk

    Denial risk from uncertain risk–benefit (prostate/cardiovascular concerns)

    Because the adverse-event profile (particularly potential prostate-related and cardiovascular harms) is uncertain in some populations (e.g., men without definite hypogonadism), these uncertainties can lead to denial or restriction when benefits are limited.

    • Provide detailed risk assessment (cardiovascular and prostate) when benefits are expected to be marginal.
    Denial Risk

    Contraindications and situations warranting avoidance

    Do not prescribe testosterone therapy for men planning fertility in the near term, men with breast or prostate cancer, palpable prostate nodule or induration, PSA >4 ng/mL (or PSA >3 ng/mL with high prostate-cancer risk without further urologic evaluation), elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, recent myocardial infarction or stroke within 6 months, or thrombophilia.

    • If any contraindicating condition is present, provide documentation and specialist evaluation if seeking an exception.
    Billing Rule

    Coverage contingent on member-specific plan terms

    Coverage and reimbursement determinations are contingent on member-specific benefit plan terms and the written medical policy; presence of listed codes does not guarantee payment.

    • Confirm coverage through the member’s benefit plan and reference the medical policy when processing authorization or claims.
    Used total testosterone <300 ng/dL (Ponce) or <275 ng/dL (NIH trials) for eligibility
    Documentation implicationPrior authorization should include both symptom documentation and a measured low total testosterone
    inv-55: Erythrocytosis (treatment-associated) — Increased incidence of elevated red blood cell parameters observed with testosterone treatment in trials and meta-analysis (reported i...).
    Observed safety signalIncreased incidence of erythrocytosis (elevated red blood cell parameters) with testosterone treatment reported in trials and meta-analysis
    Magnitude reportedPonce et al. reported increased erythrocytosis (RR ~8.14) in included RCTs
    Clinical monitoringHematocrit and hemoglobin monitoring recommended due to risk of treatment‑associated erythrocytosis
    inv-56: Populations of interest — Individuals with androgen deficiency on chronic steroid treatment; individuals with androgen deficiency and type 2 diabetes; individuals ...
    Population AIndividuals with androgen deficiency on chronic steroid treatment
    Population BIndividuals with androgen deficiency and type 2 diabetes
    Population CIndividuals with HIV infection and weight loss (studied in systematic reviews)
    inv-57: Population definitions — Individuals with androgen deficiency and type 2 diabetes; and older men with low testosterone levels without definite hypogonadism as def...
    Population: Type 2 diabetesIndividuals with androgen deficiency and type 2 diabetes (PICO population for evidence review)
    Population: Older menOlder men with low testosterone levels without definite hypogonadism (defined as a separate PICO population)
    Usage notePopulations correspond to subgroups evaluated in systematic reviews and RCTs informing coverage considerations
    inv-58: Hypogonadism vs low testosterone (context) — Many trials enrolled men with low testosterone but without pathologic hypogonadism; outcomes and risks may differ between men with clinic...
    DistinctionMany trials enrolled men with low testosterone without pathologic hypogonadism; outcomes and risks may differ between these men and those with clinical/hypogonadal pathology
    ImplicationTrial results in men with low testosterone may not generalize to men with defined hypogonadism of specific etiologies
    Coverage relevanceCoverage decisions should consider whether patient meets clinical definition of hypogonadism used in trials versus isolated low lab values
    inv-59: PSA change (SMD=0.33) — Standardized mean difference in PSA level change associated with short-term transdermal testosterone (SMD=0.33; 95% CI 0.21–0.45).
    PSA change (short-term transdermal)Standardized mean difference in PSA level change associated with short-term transdermal testosterone: SMD = 0.33 (95% CI 0.21–0.45)
    SourceCui et al. systematic review of RCTs reporting prostate outcomes
    Clinical noteShort-term PSA increases were observed with transdermal testosterone though no consistent long‑term prostate cancer association was found
    inv-60: Testicular hypofunction — ICD-10-CM code E29.1 listed in the policy's code reference for testicular hypofunction.
    ICD-10-CM codeE29.1 — Testicular hypofunction
    Coding contextListed in the policy's code reference for general reference purposes only
    Coverage noteInclusion of a code in the policy does not guarantee coverage; refer to member benefit terms

    Policy updated with literature review through May 26, 2021; references added; policy statements unchanged; Blue Cross of Idaho adopted changes effective 07/28/2022.

    2021-07-22policy_replace_and_literature_update

    Policy replaced and updated with literature review through June 3, 2020 (and later through May 26, 2021 in related notes); references added/updated; policy statements unchanged; Blue Cross of Idaho adopted changes effective 07/22/2021.